NCT00887250
A Study to Investigate the Antihypertensive Efficacy of MK0954
See it on ClinicalTrials.gov ↗366 people
35.8%
64.2%
131 womenmiddle line = equal numbers235 men
- Phase
- PHASE3
- Paid for by
- Merck Sharp & Dohme LLC
- Finished
- 1992-11
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 21 Years – no maximum
- Average age
- mean 54.0 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 81.1% · Black / African American 12.8% · Hispanic / Latina 5.2% · Other 0.8%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or lactating females”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or lactating females”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of myocardial infarction with in past year”
- No cancer
Women with current or past cancer were turned away.
“Patient has secondary hypertension or malignant hypertension”
Study titles and rules are shown in their original English.